Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tammy Ladduwahetty

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
A new class of selective, non-basic 5-HT2A receptor antagonistsTammy Ladduwahetty, Amanda L Boase, Andrew Mitchinson, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disordersTammy Ladduwahetty, Myra Gilligan, Alexander Humphries, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2005
4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomniaL Rebecca Fish, Myra T Gilligan, Alexander C Humphries, et al.
ACS Medicinal Chemistry Letters|August 27, 2016
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis ModelAndrew D Cansfield, Tammy Ladduwahetty, Mihiro Sunose, et al.
Journal of Medicinal Chemistry|September 13, 2022
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease PathologyNatsuko Macabuag, William Esmieu, Perla Breccia, et al.
Journal of Medicinal Chemistry|July 11, 2022
Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's DiseaseTammy Ladduwahetty, Matthew R Lee, Michel C Maillard, et al.
Cancer Discovery|September 2, 2022
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid LeukemiaYiman Liu, Qinglan Li, Fatemeh Alikarami, et al.
Journal of Medicinal Chemistry|September 15, 2023
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's DiseaseLongbin Liu, Karine Malagu, Alan F Haughan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
A new class of selective, non-basic 5-HT2A receptor antagonistsTammy Ladduwahetty, Amanda L Boase, Andrew Mitchinson, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disordersTammy Ladduwahetty, Myra Gilligan, Alexander Humphries, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2005
4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomniaL Rebecca Fish, Myra T Gilligan, Alexander C Humphries, et al.
ACS Medicinal Chemistry Letters|August 27, 2016
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis ModelAndrew D Cansfield, Tammy Ladduwahetty, Mihiro Sunose, et al.
Journal of Medicinal Chemistry|September 13, 2022
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease PathologyNatsuko Macabuag, William Esmieu, Perla Breccia, et al.
Journal of Medicinal Chemistry|July 11, 2022
Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's DiseaseTammy Ladduwahetty, Matthew R Lee, Michel C Maillard, et al.
Cancer Discovery|September 2, 2022
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid LeukemiaYiman Liu, Qinglan Li, Fatemeh Alikarami, et al.
Journal of Medicinal Chemistry|September 15, 2023
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's DiseaseLongbin Liu, Karine Malagu, Alan F Haughan, et al.
Pageof 1